Introduction {#Sec1}
============

When considering current epidemiologic data and immunization practices, human papillomavirus (HPV), meningococcal and tetanus-reduced diphtheria-acellular pertussis (Tdap) vaccines are among those generally recommended to be administered in adolescence \[[@CR1], [@CR2]\]. Whenever possible, concomitant administration of different vaccines, usually at different injection sites, is adopted to try to maximize the opportunities for improving compliance with vaccination schedules and community protection, as long as there is no immunologic interference among the co-administered vaccines.

A phase-4, clinical study was conducted in the USA and Italy to demonstrate non-inferiority of immune responses of a Tdap vaccine (*Boostrix*, GSK) and quadrivalent HPV vaccine (HPV4; *Gardasil*, Merck & Co., Inc.) when administered concomitantly with a quadrivalent meningococcal CRM~197~-conjugate vaccine (MenACWY-CRM; *Menveo*, GSK) or placebo in healthy adolescents aged 11--18 years. As immunogenicity results related to Tdap and MenACWY-CRM reference antigens and safety data were available, they were previously published \[[@CR3]\]. In this article, the latest available analyses pertaining to the assessment of the HPV4 immunogenicity, when the vaccine was administered concomitantly with Tdap and MenACWY-CRM or placebo, are presented.

Methods {#Sec2}
=======

This was a phase-4, multicenter, randomized, observer-blind, controlled trial (NCT01424644), conducted across 20 sites in the US and Italy between September 2011 and December 2012, in which healthy adolescents 11--18 years of age were randomized 1:1 to concomitantly receive one dose each of HPV4, Tdap and MenACWY-CRM (group HPV4 + Tdap + MenACWY) or one dose each of HPV4, Tdap and placebo (group HPV4 + Tdap + Placebo). All participants received two additional doses of HPV4, administered 2 and 6 months after the first dose. Further details on the study design, randomization, blinding, interventions and sample size calculations have been previously published \[[@CR3]\].

Eligible study participants included those who had given their written consent/assent and who had received childhood vaccinations against diphtheria, tetanus and pertussis, as per local regulations, but had not yet received any adolescent dose of vaccines against diphtheria, tetanus or pertussis. Eligible female individuals were required to have a negative urine pregnancy test and, if sexually active, to be willing to adopt appropriate birth control measures during the study period. Main exclusion criteria were: history of anaphylaxis/serious reactions to any component of the study vaccines; previous disease (confirmed or suspected) caused by *N. meningitidis*; receipt of any investigational or licensed vaccines containing meningococcal antigens or a prior HPV vaccination; history of any serious acute, chronic or progressive disease, or of an impaired immune system. A more detailed list of inclusion and exclusion criteria has been published elsewhere \[[@CR3]\].

The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines. Prior to enrollment, approval of the study protocol and protocol-related documents was obtained from the relevant Independent Ethics Committees. Informed consent was obtained from all individual participants included in the study or, for those \< 18 years of age, from their parents or legal guardians.

Here, we describe the results of the co-primary objective of the study linked to HPV4 immunogenicity, which was to demonstrate non-inferiority of the immune responses induced by HPV4 given concomitantly with Tdap and MenACWY-CRM compared with those elicited by HPV4 co-administered with Tdap and placebo, 1 month after the third HPV4 dose. Non-inferiority was demonstrated if the lower limits of the two-sided 95% confidence intervals (CIs) on the between-group differences (HPV4 + Tdap + MenACWY group minus HPV4 + Tdap + Placebo group) in seroconversion (SC) rates were \> -- 5% for each of the HPV types 6 (HPV-6), HPV-11, HPV-16 and HPV-18.

Immune responses to HPV4 vaccination were assessed using blood samples collected at baseline, before the first HPV4 dose and 1 month after the third HPV4 dose. Serum antibody levels against the four HPV types were measured by means of a validated competitive Luminex immunoassay used for the evaluation of immune responses to HPV4 during its clinical development program \[[@CR4], [@CR5]\].

SC rates were calculated at 1 month after the third HPV4 dose for each study group and HPV type as the percentage of participants with antibody titers greater or equal to a HPV type-specific cutoff and were seronegative at baseline (i.e., had antibody titers lower than the cutoff value). The pre-established cutoff value was 16 milliMerck units (mMU)/ml for HPV-11, 20 mMU/ml for HPV-6 and HPV-16, and 24 mMU/ml for HPV-18. The associated two-sided 95% CIs for SC rates in each group were calculated using the Clopper-Pearson method \[[@CR6]\], and those for the between-group differences in SC rates were computed using the Miettinen-Nurminen method \[[@CR7]\].

Geometric mean antibody titers (GMTs) and geometric mean ratios (GMRs; post-vaccination over baseline antibody levels) were also calculated by study group, by exponentiating (base~10~) the corresponding least square means of the log~10~-transformed titers. The associated 95% CIs were derived using the analysis of variance (ANOVA), with study group and center in the model.

The main immunogenicity analysis population was the HPV per-protocol (HPV-PP) set, which included all participants without major protocol deviations, who correctly received all vaccine doses and for whom evaluable serum samples were available for at least one HPV type at both baseline and at 1 month post-third dose, with vaccine injection and blood draw occurring within the protocol-required windows.

Assuming a 10% dropout rate, approximately 800 individuals were planned to be enrolled in the study (400 per vaccine group) to obtain a sample size of 360 evaluable participants in each group. The power to demonstrate non-inferiority for each HPV type was ≥ 99.8%, using a non-inferiority margin of − 5%. More details on the study sample size calculation and overall study power have been reported previously \[[@CR3]\].

Results {#Sec3}
=======

Of the 801 participants enrolled in this study (247 in Italy and 554 in the US), 634 were included in the HPV-PP set: 309 in the HPV4 + Tdap + MenACWY group and 325 in the HPV4 + Tdap + Placebo group. The main reasons for exclusion were administration of prohibited vaccination and non-compliance with vaccination or blood draw schedule. The demographic characteristics of participants in the HPV-PP set were overall balanced between the study groups. The mean age of the participants was 11.9 (± 1.6) years, and 38% were females (Table [1](#Tab1){ref-type="table"}).Table 1Characteristics of study participants at baseline (HPV per-protocol population)Group HPV4 + Tdap + MenACWYGroup HPV4 + Tdap + PlaceboTotalN309325634Mean age (± SD), years11.9 ± 1.6311.8 ± 1.4811.9 ± 1.56Female, *n* (%)124 (40%)116 (36%)240 (38%)Ethnicity, *n* (%) Asian3 (1%)6 (2%)9 (1%) Black or African25 (8%)26 (8%)51 (8%) Caucasian253 (82%)260 (80%)513 (81%) American Indian/Alaskan Native1 (\< 1%)1 (\< 1%)2 (\< 1%) Pacific/Hawaii02 (1%)2 (\< 1%) Other27 (9%)30 (9%)57 (9%)Mean weight (± SD), kg50.22 ± 14.8149.92 ± 15.0850.07 ± 14.94Mean height (± SD), cm153.1 ± 11.72153.3 ± 11.09153.2 ± 11.39Mean body mass index (± SD), kg/m^2^21.2 ± 4.6821 ± 4.8221.1 ± 4.75*HPV* human papillomavirus, *HPV4* quadrivalent HPV vaccine, *Tdap* tetanus-diphtheria-acellular pertussis vaccine, *MenACWY* quadrivalent meningococcal conjugate vaccine, *N* number of participants in each group, *SD* standard deviation, *n (%)* number (percentage) of participants in each category

One month after the third HPV4 dose, SC rates ranged between 98.0% (HPV-6) and 99.7% (HPV-11 and HPV-18) in HPV4 + Tdap + MenACWY group and between 99.0% (HPV-11 and HPV-16) and 99.7% (HPV-6 and HPV-18) in the HPV4 + Tdap + Placebo group (Fig. [1](#Fig1){ref-type="fig"}a). Differences between the SC rates in the HPV4 + Tdap + MenACWY group and HPV4 + Tdap + Placebo group were − 1.0% (95% CIs − 3.5% to 0.3%) for HPV-6, 0.3% (95% CIs − 1.2% to 1.9%) for HPV-11, 1.0% (95% CIs − 1.2% to 2.6%) for HPV-16 and 0.0% (95% CIs − 1.5% to 1.4%) for HPV-18, with the lower limit of the 95% CIs being \> − 5% for each tested HPV type (Fig. [1](#Fig1){ref-type="fig"}b). Therefore, immune responses to HPV4 given concomitantly with Tdap and MenACWY-CRM were shown to be non-inferior to the responses of HPV4 when co-administered with Tdap and placebo.Fig. 1Summary of immune responses to HPV types: seroconversion rates (**a**) and between-group difference in seroconversion rates (**b**), geometric mean titers (**c**) and geometric mean ratios (**d**). *HPV* human papillomavirus, *HPV4* quadrivalent HPV vaccine, *Tdap* tetanus-diphtheria-acellular pertussis vaccine, *MenACWY* quadrivalent meningococcal conjugate vaccine, *mMU* milliMerck units, *M7* month 7 (1 month post-third HPV4 dose). Error bars represent 95% confidence intervals

At baseline, GMTs were similar between the two groups for each HPV type. One month post-third HPV4 dose, robust antibody responses were observed in both groups for all HPV types (Fig. [1](#Fig1){ref-type="fig"}c). GMTs ranged between 1012.60 (HPV-6) and 6293.21 (HPV-16) in the HPV4 + Tdap + MenACWY group and between 1084.13 (HVP-6) and 7221.71 (HPV-16). GMTs were comparable between groups, with overlapping 95% CIs, when analyzed by HPV type (Fig. [1](#Fig1){ref-type="fig"}c).

One month post-third HPV4 dose, GMRs ranged between 173.85 (HPV-6) and 1111.67 (HPV-16) in the HPV4 + Tdap + MenACWY group and between 191.15 (HPV-6) and 1277.5 (HPV-16) in the HPV4 + Tdap + Placebo group (Fig. [1](#Fig1){ref-type="fig"}d). Overall, GMTs and GMRs were higher against HPV-16 and lower against HPV-6, irrespective of the study group.

Discussion {#Sec4}
==========

The analyses on the immunogenicity of the HPV4 vaccine administered concomitantly with Tdap and MenACWY-CRM or placebo confirmed previously reported data, supporting the co-administration of the three vaccines with no impact on the immunogenicity of each vaccine antigen \[[@CR8]\] or safety \[[@CR3], [@CR8]\]. Overall, the mean age of the population enrolled in this study was 11.9 years, which was in line with the age range generally recommended for HPV routine vaccination (11--12 years) \[[@CR1], [@CR2]\].

When HPV4 was co-administered with Tdap and the MenACWY-CRM, SC rates for all tested HPV types were ≥ 98% and were non-inferior to those observed when placebo was given instead of MenACWY-CRM. Post-vaccination GMTs and ratios were comparable between study groups, when analyzed by HPV type, with higher titers observed against HPV-16 and lower against HPV-6. In the same study, as previously reported \[[@CR3]\], 1 month post-vaccination, 95% and 99% of participants in the MenACWY-CRM group had seroprotective antibody levels ≥ 1.0 IU/ml) against the diphtheria and tetanus toxoids, respectively, compared with 82% and 98% among the placebo recipients. Ratios of geometric mean concentrations of antibodies against pertussis antigens, pertussis toxin, filamentous hemagglutinin and pertactin for the MenACWY-CRM group versus placebo were 1.01, 0.84 and 0.82, respectively. Overall, non-inferiority criteria for immunologic responses against all Tdap antigens were met. In addition, administration of a single dose of MenACWY-CRM elicited robust antibody responses against the four meningococcal serogroups, with 77%, 84%, 95% and 86% of participants showing human complement serum bactericidal antibody titers ≥ 8 against serogroups A, C, W and Y, respectively \[[@CR3]\].

Previous studies have assessed the co-administration of a different quadrivalent meningococcal conjugate vaccine with HPV and Tdap vaccines. A study in 10--17-year-old adolescents showed non-inferior immune responses to HPV4 when a quadrivalent diphtheria-toxoid conjugate vaccine (*Menactra*, Sanofi Pasteur Inc., France) and a Tdap vaccine (*Adacel,* Sanofi Pasteur Inc., France) were given concomitantly with the first HPV4 dose or 1 month later \[[@CR9]\]. Another trial using the same vaccination schedule showed similar results in adolescents aged 11--15 years with a nonavalent HPV vaccine (*Gardasil*-*9*, Merck & Co., Inc., USA) instead of HPV4 \[[@CR10]\].

Another study assessed HPV4, Tdap and MenACWY-CRM, but compared concomitant with sequential administration of the three vaccines \[[@CR8]\]. Responses to HPV4 were robust and comparable among vaccination schedules \[[@CR8]\], showing that concomitant administration of the three vaccines does not impact the individual immune responses to HPV types, consistent with observations in the current study.

When comparing safety data from participants exposed to the HPV4 vaccine concomitantly administered with Tdap and MenACWY-CRM with those recorded in participants exposed to HPV4, Tdap and placebo, similar percentages of participants in the current study reported any adverse events \[51% versus 50%, respectively, with injection site pain (7% versus 6%) and pharyngitis (6% versus 5%) being the most frequent ones\] \[[@CR3]\]. A similar incidence was observed in the two groups for medically attended adverse events (20% and 24%, respectively, none judged as related to the study vaccines) and new onset of chronic disease (6% and 7%, respectively), with the most frequently reported chronic conditions being seasonal allergies and minor dermatology conditions, such as acne and atopic dermatitis, consistent with expected patterns for this age group. Overall, seven participants (four in the HPV + Tdap + MenACWY group and three in the HPV + Tdap + Placebo group) reported nine serious adverse events during the entire study period; none of these were considered to be related to study vaccines \[[@CR3]\].

Potential limitations of the study included the absence of a HPV4 + MenACWY + Placebo arm and the fact that the results have been mainly generated in individuals aged 11--12 years (which is the age generally recommended for HPV vaccination) and not in older adolescents.

Conclusion {#Sec5}
==========

Immunogenicity results for HPV types, together with the previously evaluated immune responses to the meningococcal, tetanus, diphtheria and pertussis antigens and safety data, further reinforce the feasibility of HPV4, Tdap and MenACWY-CRM concomitant administration in adolescents.
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